Medically reviewed by Dr Gurpreet Singh Bassi
Last reviewed: 12th June 2026
Sign up to receive the latest information about the Wegovy pill, including UK availability updates and relevant news as it becomes available.
The Wegovy pill is an oral weight loss treatment that contains semaglutide, the same active ingredient found in Wegovy injections. It is designed to support weight management by helping to regulate appetite and food intake.
Following approval by the Medicines and Healthcare products Regulatory Agency (MHRA) in June 2026, the Wegovy pill became the first GLP-1 tablet licensed for weight management in the UK.
Unlike Wegovy injections, which are administered once weekly using a pre-filled pen, the Wegovy pill is taken as a tablet once a day. For some people, this may provide a more convenient alternative to injectable treatment.
The Wegovy pill is intended to be used alongside healthy lifestyle changes, including a balanced diet and regular physical activity.
In this guide, the WePrescribe team explains how the Wegovy pill works, how it compares to Wegovy injections, potential side effects and what approval means for patients in the UK.
The Wegovy pill contains semaglutide, a medicine that mimics the action of glucagon-like peptide-1 (GLP-1), a hormone naturally produced by the body after eating.
GLP-1 helps regulate appetite and blood sugar levels. By mimicking this hormone, semaglutide can help people feel fuller for longer and reduce overall food intake.
The Wegovy pill works by:
Together, these effects can help support long-term weight management when combined with lifestyle changes.
Learn more in our guide to 10 Important Facts About Wegovy You Need to Know.
Some people may notice a reduction in appetite within the first few days or weeks of treatment.
However, weight management treatments are designed to support gradual and sustainable weight loss over time. Individual experiences can vary depending on factors such as starting weight, treatment adherence, lifestyle changes and dosage.
If prescribed, your WePrescribe pharmacist can provide guidance on what to expect during treatment and how progress may be monitored.
Clinical studies of oral semaglutide have shown promising results in adults living with overweight and obesity.
Research has demonstrated significant reductions in body weight compared with placebo treatment, with many participants achieving clinically meaningful weight loss over the course of treatment.
As with all weight management treatments, results vary between individuals. The most successful outcomes are typically seen when medication is used alongside long-term improvements to diet, physical activity and overall lifestyle habits.
For more information, read our guide to BMI and Weight Loss.
Yes. The Wegovy pill has now received regulatory approval in the UK.
Availability may vary as supply arrangements, prescribing pathways and provider access are introduced following approval.
Patients interested in learning more can register their interest to receive updates from us at WePrescribe as further information becomes available.
The Wegovy pill is expected to be prescribed for adults who meet specific clinical eligibility criteria.
Suitability will depend on several factors, including:
A WePrescribe pharmacist/prescriber or other qualified healthcare professional would assess whether treatment is appropriate following a clinical consultation.
Not everyone seeking weight management treatment will be suitable for semaglutide-based medication.
Not sure what happens during an assessment? Read What to Expect From an Online Weight Management Consultation.
Both the Wegovy pill and Wegovy injection contain semaglutide and work through similar biological mechanisms.
The primary difference is how the medication is taken.
Some people may prefer the convenience of a daily tablet, while others may prefer the simplicity of a once-weekly injection.
The most suitable option will depend on individual preferences and clinical circumstances.
Alongside the approval of the Wegovy pill, a 7.2mg dose of the Wegovy injection is now available in the UK.
The higher-dose injection contains the same active ingredient, semaglutide, and offers an additional treatment option for eligible patients who may benefit from a higher maintenance dose as part of their weight management plan.
Both the Wegovy pill and Wegovy injection work by targeting GLP-1 receptors to help regulate appetite and food intake. However, the way they are taken differs significantly, with the tablet taken daily and the injection administered weekly.
If you’re unsure which option may be most suitable, a WePrescribe pharmacist can discuss the available treatments and explain how prescribing decisions are made following a clinical assessment.
It may be possible for some patients to switch between treatment formats under medical supervision.
Once Wegovy pill becomes available through WePrescribe, our pharmacist prescribers would be able to advise eligible patients on appropriate treatment options and any potential switch from existing therapies.
Patients should never change treatment without professional medical guidance.
The Wegovy pill should always be taken exactly as prescribed.
Patients are generally advised to:
Always follow the instructions provided with your prescription and any guidance given by your WePrescribe pharmacist.
The Wegovy pill is expected to follow a gradual dose-escalation schedule, starting at 1.5mg, moving through to 4mg, 9mg and 25mg.
Starting on a lower dose allows the body time to adjust and may help reduce the likelihood of side effects.
Your prescriber will determine the most appropriate dosing schedule based on prescribing guidance and your individual response to treatment.
As the Wegovy pill contains semaglutide, its side effect profile is similar to other GLP-1 medicines.
Common side effects may include:
Most side effects are mild to moderate and often improve as your body adjusts to treatment.
Not everyone experiences side effects, and individual experiences may vary.
Many side effects occur during the first few weeks of treatment or following a dose increase.
For most people, symptoms improve as the body becomes accustomed to the medication.
If side effects become severe, persistent or concerning, you should speak to your GP, NHS 111 or a WePrescribe pharmacist for further advice.
Simple measures may help reduce common gastrointestinal side effects:
Patients should always follow the advice provided by their healthcare professional.
Seek urgent medical attention if you experience severe abdominal pain, persistent vomiting or symptoms that make you feel seriously unwell.
As a prescription-only medicine, the Wegovy pill cannot be supplied without an appropriate clinical assessment.
When Wegovy pill becomes available through WePrescribe, patients would need to complete an online consultation, which is reviewed by a qualified prescriber.
Treatment would only be supplied where clinically appropriate and where a prescriber determines it is suitable for the individual patient.
No. The Wegovy pill is a prescription-only medicine and cannot be purchased over the counter.
A prescription from an authorised healthcare professional is required before treatment can be supplied.
NHS access arrangements will depend on national and local commissioning decisions, prescribing guidance and eligibility criteria.
If NHS access is offered, treatment is likely to be prioritised for patients who meet specific clinical requirements.
For the latest NHS guidance, patients should speak with their GP or healthcare team.
There are several prescription weight management treatments available in the UK.
The most appropriate option will depend on your medical history, treatment goals and clinical suitability.
Available options may include:
A WePrescribe pharmacist can help explain the available options and determine which approach may be appropriate for your circumstances.
Compare the differences in our guide on weight loss treatments.
The approval of the Wegovy pill marks an important development in weight management treatment, providing a new oral option for eligible patients.
Register your interest to receive updates from WePrescribe about availability, prescribing information, eligibility criteria and guidance from our pharmacist team.
Please note that registering your interest with us does not guarantee eligibility for treatment. Any future prescription would be subject to a clinical assessment and approval by a qualified prescriber.
Stay informed with our latest update: What’s New For Weight Loss Medications in 2026?
Sign up to receive the latest information about the Wegovy pill, including UK availability updates and relevant news as it becomes available.